Sfoglia per AUTORE
GAY F
Collezione AO Cuneo

  

Items : 9

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.

2023
AO Cuneo
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Sonneveld P; Vangsted AJ; Benjamin R; Hájek R; Silkjaer T; Caers J; Zweegman S; Mancuso K; Razawy W; Tacchetti P; Offidani M; Grasso M; Giaccone L; van der Velden VHJ; Pour L; Lund T; Gadisseur A; Pietrantuono G; Roeloffzen WWH; Broijl A; Schjesvold F; Wu KL; van der Holt B; Minnema MC; van de Donk NWCJ;

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.

2023
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Tacchetti P; Zucchetta P; Pascarella A; Villanova T; De Cicco G; Patriarca F; Fioritoni F; Priola C; Sgherza N; Grasso M; Versari A; Bertamini L; Gamberi B; Albano D; Zambello R; Racca M; Galli M; Belotti A; D'Agostino M; Rota-Scalabrini D; Capra A; Gay F; Oliva S; Zamagni E; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

2023
AOU Città della Salute di Torino
AO Cuneo

Boccadoro M; Gay F; Ballanti S; Belotti A; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Grasso M; Zamagni E; Fioritoni F; Cea M; Pescosta N; Vincelli ID; Ronconi S; Pavone V; Capra A; Oddolo D; de Fabritiis P; Palmas A; Mina R; Paris L; Aquino S; Gamberi B; Rota-Scalabrini D; Musto P;

Standardization of (18)F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Jan 10;39(2):116-125. doi: 10.1200/JCO.20.00386. Epub 2020 Nov 5.

2021
AO Cuneo

Kraeber-Bodéré F; Bodet-Milin C; Cavo M; Fanti S; Perrot A; Gay F; Sonneveld P; Karlin L; Barbato S; Garderet L; Boccadoro M; Macro M; Patriarca F; Caillot D; Gallamini A; Gamberi B; Chauvie S; Tacchetti P; Versari A; Bailly C; Nanni C; Carlier T; Dozza L; Zamagni E; Moreau P;

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Boccadoro M; Cavo M; Corradini P; Petrucci MT; Zambello R; Gamberi B; Aquino S; Palmas A; de Fabritiis P; Giuliani N; D'Agostino M; Capra A; Patriarca F; Cea M; Spadano A; Grasso M; Ballanti S; Zamagni E; Ledda A; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino
AO Cuneo

Sonneveld P; Boccadoro M; Carvalho S; Spencer A; Palmas A; Cafro AM; Minnema M; Mandigers C; van Marwijk Kooy M; Gimsing P; Mellqvist UH; Waage A; Driessen C; Specchia G; Zander T; Caravita di Toritto T; Durian M; von dem Borne PA; Hajek R; Wu KL; Boersma R; Morelli AM; Aquino S; Ludwig H; Levin MD; Bos G; Pascarella A; Benevolo G; Troia R; et alii...

Standardization of 18F-FDG PET/CT according to deauville criteria for MRD evaluation in newly diagnosed transplant eligible multiple myeloma (MM) patients: Joined analysis of two prospective randomized phase III trials in Haematologica

2019
AO Cuneo

Zamagni E; Nanni C; Dozza L; Carlier T; Tacchetti P; Versari A; Chauvie S; Gallamini A; Attal M; Gamberi B; Caillot D; Patriarca F; MacRo M; Boccadoro M; Garderet L; Fanti S; Perrot A; Gay F; Sonneveld P; Karlin L; Bodet-Milin C; Moreau P; Kraeber-Bodéré F; Cavo M;

Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21

2018
AO Cuneo
AOU Città della Salute di Torino

Zamagni E; Cavo M; Gamberi B; Ghedini P; Gay F; Patriarca F; Gallamini A; Rensi M; Bellò M; Chauvie S; Bertone E; Bianchi A; Nanni C; Versari A; Fanti S;

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.

2016
AO Cuneo
AOU Città della Salute di Torino

Fanti S; Cavo M; Gamberi B; Gay F; Patriarca F; Gallamini A; Rambaldi I; Bellò M; Rensi M; Bianchi A; Chauvie S; Versari A; Zamagni E; Nanni C;